Goal of the analysis:
Develop a clear regulatory approach for products that combine drugs, devices, or biologics. This includes determining the primary mode of action, identifying the lead regulatory authority, and outlining the path to approval or clearance (for example, FDA’s Office of Combination Products).
Data required:
- Detailed description of each constituent part (device, drug, biologic)
- Intended use and indications for use of the combination product
- Primary mode of action (PMOA) and secondary modes of action
- Existing regulatory classifications for each constituent component, if available
- Clinical data or scientific rationale for combining the components
- Relevant regulatory guidance documents (for example, FDA Guidance on Combination Products)
Detailed step-by-step instruction on how to conduct the analysis:
- Identify the constituent parts and their regulatory status. Determine if each component is separately approved or cleared (drug, device, or biologic) and note their classifications.
- Determine the primary mode of action (PMOA). Assess which component provides the most significant therapeutic benefit to categorize the combination product under the appropriate regulatory pathway.
- Review relevant guidance documents. Consult agency-specific guidelines (for example, FDA guidance) to confirm the correct lead center (CDER, CDRH, or CBER) for regulatory oversight.
- Evaluate data requirements for each component. Identify clinical, preclinical, manufacturing, and labeling requirements for both the primary and secondary components.
- Outline a regulatory submission strategy. Decide if a single marketing application or multiple submissions are needed (for example, a single 510(k) vs. a PMA plus a new drug application).
- Assess labeling and risk management. Ensure that combination product labeling addresses safety, efficacy, warnings, and instructions for both components.
- Identify any unique testing or clinical trial obligations. Determine if additional studies are required to confirm the safety and effectiveness of the combined product.
- Document findings in a strategic roadmap. Provide an overview of the regulatory approach, responsibilities, timelines, and anticipated challenges.
Format of the output of analysis:
- A written strategic roadmap summarizing the combination product classification, lead regulatory authority, and submission strategy
- A table mapping each component to its regulatory requirements and any additional data needed
- A high-level timeline outlining development milestones, submissions, and approval or clearance expectations
How to interpret results:
- Properly determining PMOA and lead authority ensures the combination product follows the correct regulatory pathway, reducing review delays.
- Overlapping or conflicting requirements between components may indicate a need for more in-depth regulatory consultation.
- A clear, structured submission strategy helps align cross-functional teams and avoids duplicated efforts.
Steps a company can take to improve on this measure:
- Engage early with regulatory agencies, such as requesting a designation letter or holding pre-submission meetings.
- Build cross-functional teams (regulatory, clinical, manufacturing) to address combination product complexities.
- Keep up to date with emerging combination product guidelines and evolving regulatory expectations.
- Establish robust risk management processes that integrate both device and drug/biologic components.
- Continuously refine the submission strategy based on feedback from regulatory authorities and updated guidance.
